Eagle Pharmaceuticals (NASDAQ:EGRX) Earns Hold Rating from Analysts at StockNews.com

Research analysts at StockNews.com began coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a research report issued to clients and investors on Wednesday. The firm set a “hold” rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Stock Performance

Shares of NASDAQ EGRX opened at $0.90 on Wednesday. The company has a 50 day simple moving average of $2.09 and a 200-day simple moving average of $3.74. Eagle Pharmaceuticals has a 1 year low of $0.00 and a 1 year high of $9.89.

Institutional Investors Weigh In On Eagle Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Perceptive Advisors LLC acquired a new stake in shares of Eagle Pharmaceuticals during the 2nd quarter worth about $971,000. Cubist Systematic Strategies LLC purchased a new stake in shares of Eagle Pharmaceuticals in the 2nd quarter valued at approximately $145,000. AIGH Capital Management LLC boosted its position in shares of Eagle Pharmaceuticals by 2.1% during the 2nd quarter. AIGH Capital Management LLC now owns 1,211,509 shares of the specialty pharmaceutical company’s stock worth $6,784,000 after purchasing an additional 25,000 shares during the period. XTX Topco Ltd acquired a new stake in Eagle Pharmaceuticals in the 2nd quarter valued at approximately $113,000. Finally, Price T Rowe Associates Inc. MD purchased a new stake in Eagle Pharmaceuticals in the first quarter valued at approximately $83,000. Hedge funds and other institutional investors own 85.36% of the company’s stock.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.